InspireMD, Inc. Q2 2026 Earnings Call Summary

InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.

Original reporting
Published Aug 17, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
InspireMD, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

Med
01

Why it matters

Traders can update probability-weighted timelines for (1) FDA approval of CGuard Prime 80 (TCAR) and CGuard CAS in Q4 2026, (2) potential accelerated review for the redesigned CGuard Prime 135 delivery system, and (3) SwitchGuard’s back-half 2027 approval path, while also reassessing near-term cash runway after recall and restructuring charges.

02

Market read

The article provides concrete recall-related financial impacts and specific FDA timing targets that can move valuation via updated commercialization probabilities.

03

What to watch

Cash fell to $30.4M and restructuring charges are expected in Q3 2026, which could increase dilution or financing risk before relaunch revenue materializes.

Relevance 7/10Novelty 6/10Timing: ahead of Q4 2026 FDA decision window and H1 2027 CGuard Prime 135 reentry

Background

This is a Q2 2026 earnings call summary focused on InspireMD’s CGuard stent platform recall, cost actions, and FDA approval/relaunch timelines.

Market effects

Highlights how delivery-system recalls can shift FDA timelines and force cost restructuring in medical device stent/TCAR workflows.

No specific regional market impact beyond international growth commentary.

US FDA approval timing remains the key driver for global commercialization expectations.

Counterpoint

The optimism around accelerated review and pent-up demand may be overly optimistic given the stated long poles (biocompatibility testing and statutory review).

Key entities

  • InspireMD, Inc.

    Subject of the earnings call summary; discussed recall impacts, restructuring, cash position, and FDA relaunch milestones for CGuard and SwitchGuard.

  • CGuard Prime 135

    Voluntarily recalled delivery system; drove customer credits, inventory impairment, and a redesign/reentry plan.

  • CGuard Prime 80 (TCAR) and CGuard CAS

    Management anticipates potential FDA approval for both in Q4 2026.

  • SwitchGuard neuroprotection system

    Tracking toward back-half 2027 US approval; CGUARDIANS III enrollment underway.

Related articles

$NSPRHighAI 8/10

InspireMD (NSPR) Q3 2026 Earnings Call Transcript

InspireMD (NSPR) announced FDA approval for its CGuard Prime TransCarotid Stent System, expanding U.S. market access by 40,000 annual procedures. Q3 2026 international revenue grew 9% YoY to $2.2M. The company plans commercial execution and cost alignment, with a 20% workforce reduction. FDA submission for the CGuard Prime 135 CAS delivery system is expected by year-end.

$NSPRLow

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHigh

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR